Please login to the form below

Not currently logged in
Email:
Password:

Novartis Oncology head Bruno Strigini to retire

Will leave the Swiss pharma firm, and the industry, next year

Novartis Bruno StriginiThe head of Novartis Oncology Bruno Strigini is set to step down and retire from the pharmaceutical industry.

Citing personal reasons, the Swiss pharma firm said Strigini would step back from his place on its executive committee by December 31 and leave his current role in early 2018.

Novartis CEO Joseph Jimenez said: "I'd like to thank Bruno Strigini for his contributions and achievements. He has navigated the business unit through the Gleevec patent expiration and has led the successful integration of the GSK Oncology Product Portfolio acquired in 2015. I wish him the best for his future."

Strigini joined Novartis in 2014 from Merck & Co, where he spent nearly five years as president, Europe and Canada.

Prior to that he served in a similar role at Schering-Plough, before its acquisition by Merck in 2009.

19th December 2017

From: Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Research Partnership

We are one of the largest independent healthcare market research and consulting agencies in the world. Trusted partner to the...

Latest intelligence

No incentive for a cure
The paradox of ‘cost-effective but unaffordable’ life-saving medicines...
Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...

Infographics